{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Protein Production Technology Podcast","title":"Rocío Duchén Bocángel, Argenta | What the FDA’s Proposed GRAS Rule Means for Food Innovators","html":"","width":"100%","height":180,"duration":2485,"description":"Powered by Protein Production Technology International\nThe US Food and Drug Administration (FDA) has proposed significant changes to the Generally Recognized as Safe (GRAS) system, including mandatory notification for certain uses of substances in human and animal food. For ingredient manufacturers, particularly those developing novel proteins and fermentation-derived ingredients, the proposal raises important questions about regulatory strategy, transparency, timelines, and cost.\nIn this episode of the Protein Production Technology International Podcast, Nick Bradley speaks with Rocío Duchén Bocángel, Principal Regulatory Affairs Manager at Argenta, about the proposed rule and what it could mean for companies bringing new food ingredients to the US market.\nRocío explains the distinction between a GRAS conclusion and FDA approval, why notification does not constitute an ingredient registration, and how the proposed changes could affect companies currently relying on self-affirmed GRAS conclusions. The discussion explores the proposed streamlined process for ingredients already on the market, the documentation manufacturers should review, and the potential administrative and economic burden of mandatory notification.\nThe conversation also examines the implications for emerging food technologies, including precision-fermented proteins, microbial ingredients, and other novel sources. Rocío discusses how regulatory requirements can vary depending on the production organism, the ingredient’s characteristics, allergenicity, toxicology, and the intended use of the substance.\nWith the proposed rule still subject to change, the episode considers the importance of building regulatory strategy into product development from the outset. Rocío also highlights the potential challenges around FDA review capacity, the impact on startups, and the role greater transparency could play in shaping confidence across the food industry.\nFor companies developing ingredients for the US...","thumbnail_url":"https://img.transistorcdn.com/tUifNxYi7y1wl92YvdM05mMBe8G47RO6Jcub5_A_xxY/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzM5MjkxLzE2OTk5/NTU4MzQtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}